Manuel Litchman
Net Worth

Last updated:

What is Manuel Litchman net worth?

The estimated net worth of Dr. Manuel Litchman is at least $5,930,483 as of 27 Oct 2021. He owns shares worth $1,644,779 as insider, has earned $37,614 from insider trading and has received compensation worth at least $4,248,090 in Mustang Bio, Inc..

What is the salary of Manuel Litchman?

Dr. Manuel Litchman salary is $606,870 per year as Pres, Chief Executive Officer & Director in Mustang Bio, Inc..

How old is Manuel Litchman?

Dr. Manuel Litchman is 71 years old, born in 1954.

What stocks does Manuel Litchman currently own?

As insider, Dr. Manuel Litchman owns shares in one company:

Company Title Shares Price per share Total value
Mustang Bio, Inc. (MBIO) Pres, Chief Executive Officer & Director 1,027,987 $1.6 $1,644,779

What does Mustang Bio, Inc. do?

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

MBIO logo
MBIO
Mustang Bio, Inc.
$1.6

Manuel Litchman insider trading

Mustang Bio, Inc.

Dr. Manuel Litchman has made only one insider trade between 2018-2021, according to the Form 4 filled with the SEC. He purchased 65,000 units of MBIO stock worth $145,600 on 27 Oct 2021.

As of 27 Oct 2021 he still owns at least 1,027,987 units of MBIO stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
COMMON STOCK 65,000 $2.24 $145,600
Purchase
COMMON STOCK 86,206 $2.91 $250,859
Purchase
COMMON STOCK 165,562 N/A N/A
Purchase
COMMON STOCK 100,000 N/A N/A
Purchase
COMMON STOCK 153,846 N/A N/A
Sale
COMMON STOCK 12,373 $3.04 $37,614
Purchase
Common Stock 90,000 N/A N/A
Purchase
Common Stock 90,000 N/A N/A
Purchase
Common Stock 8,000 N/A N/A
Purchase
Common Stock 7,500 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 2,500 N/A N/A

Mustang Bio key executives

Mustang Bio, Inc. executives and other stock owners filed with the SEC: